SFRP1 and neoplasm: decrease in pro-osteogenic Wnt5a and Wnt10b signaling- decreased AXL dormancy signaling, - enhanced MERTK tumor promoting signaling. - Altered balance of sFRP2 canonical protumorigenic Wnt/β-catenin antagonist and sFRP1 dormancy sustainer